Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cero Therapeutics Holdings Inc (CERO)

Cero Therapeutics Holdings Inc (CERO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,365
  • Shares Outstanding, K 150,313
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,540 K
  • EBIT $ -14 M
  • EBITDA $ -14 M
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.42
  • Most Recent Earnings $-0.09 on 11/19/24
  • Next Earnings Date 02/18/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0467 +28.48%
on 12/17/24
0.2549 -76.46%
on 11/27/24
-0.0870 (-59.18%)
since 11/26/24
3-Month
0.0467 +28.48%
on 12/17/24
0.4477 -86.60%
on 11/15/24
-0.0343 (-36.37%)
since 09/26/24
52-Week
0.0467 +28.48%
on 12/17/24
12.8000 -99.53%
on 02/06/24
-10.9700 (-99.46%)
since 12/22/23

Most Recent Stories

More News
Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERO : 0.0600 (-3.69%)
NKGN : 0.8741 (+11.12%)
IMRX : 2.18 (-3.11%)
AZTR : 0.4077 (-0.07%)
PBM : 2.39 (-1.65%)
Insider Sale: 10% owner at $CERO (CERO) Sells 1,343,801 Shares

Bioventures Opportunities GP I, LLC YK, a 10% owner of $CERO ($CERO), sold 1,343,801 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

CERO : 0.0600 (-3.69%)
Insider Sale: 10% owner at $CERO (CERO) Sells 1,236,874 Shares

Bioventures Opportunities GP I, LLC YK, a 10% owner of $CERO ($CERO), sold 1,236,874 shares of the company on 12-06-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

CERO : 0.0600 (-3.69%)
CERo Therapeutics Appoints Chris Ehrlich as CEO, Advances Clinical Development of CER-1236

CERo Therapeutics appoints Chris Ehrlich as CEO, advancing cancer immunotherapy development, including plans for clinical trials in 2025.Quiver AI SummaryCERo Therapeutics Holdings, Inc. has announced...

CERO : 0.0600 (-3.69%)
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERO : 0.0600 (-3.69%)
CERo Therapeutics Announces FDA Clearance of IND for Phase 1 Trials of CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics received FDA clearance for Phase 1 trials of CER-1236 in acute myelogenous leukemia.Quiver AI SummaryCERo Therapeutics Holdings, Inc. announced that the U.S. FDA has cleared its Investigational...

CERO : 0.0600 (-3.69%)
CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERO : 0.0600 (-3.69%)
CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERO : 0.0600 (-3.69%)
CERo Therapeutics, Inc. Provides Corporate Update

CERO : 0.0600 (-3.69%)
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that

CERO : 0.0600 (-3.69%)

Business Summary

CERo Therapeutics Holdings Inc. is an immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. The company's lead product candidate includes CER-1236. CERo Therapeutics Holdings Inc., formerly known as Phoenix Biotech Acquisition Corp.,...

See More

Key Turning Points

3rd Resistance Point 0.0712
2nd Resistance Point 0.0673
1st Resistance Point 0.0637
Last Price 0.0600
1st Support Level 0.0562
2nd Support Level 0.0523
3rd Support Level 0.0487

See More

52-Week High 12.8000
Fibonacci 61.8% 7.9282
Fibonacci 50% 6.4234
Fibonacci 38.2% 4.9185
Last Price 0.0600
52-Week Low 0.0467

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar